Image

Global Cancer Diagnostics Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Jul 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Cancer diagnostics Market, By Type (Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy, Others), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma Cancer, Prostate Cancer, Liver Cancer, Others), End-User (Diagnostic Centres, Hospitals and Clinics, Research Institutes, Others) – Industry Trends and Forecast to 2029

 

Cancer Diagnostics Market

Market Analysis and Size

Cancer has a significant impact on society all over the world. It is one of the leading causes of death worldwide, with a higher prevalence in developed and emerging markets. The alarming rate of rising cancer prevalence compels healthcare providers to reconsider cancer treatment goals and shift their focus to prevention. Cancer diagnostics that are not only specific and sensitive, but also capable of detecting cancer in its early stages would be required.

Data Bridge Market Research analyses that the cancer diagnostics market is expected to reach the value of USD 28.21 billion by the year 2029, at a CAGR of 7.29% during the forecast period. The rise in the Cancer cases provides growth opportunities to the market.

Market Definition

Cancer diagnostics is the process of detecting various biomarkers, proteins, and symptoms that lead to the presence of a cancerous tumour in patients. The detection of specific biomarkers and proteins that are common in cancer disorders leads to the diagnosis process. The process of detecting cancer includes the use of specific technology and devices used in its diagnosis.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy, Others), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma Cancer, Prostate Cancer, Liver Cancer, Others), End-User (Diagnostic Centres, Hospitals and Clinics, Research Institutes, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, Sweden, Poland, Denmark, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Global (APAC) in the Global (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Abbott. (US), DiagnoCure Inc. (Canada), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), QIAGEN (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), Quest Diagnostics Incorporated. (US), Merck KGaA, (Germany), Hologic, Inc. (US), BD. (US), GlaxoSmithKline plc. (UK), Novartis AG (Switzerland), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Pfizer, Inc. (US), Genomic Health, Inc. (US), bioMérieux SA (France), Astellas Pharma Inc. (Japan) and Myriad Genetics, Inc. (US)

Cancer diagnostics Market Dynamics

Drivers

  • The rise in the cases of cancer

Cancer is the world's second leading cause of death, accounting for 10 million deaths by 2020. Cancer accounts for approximately one-sixth of all deaths worldwide (Source: World Health Organization). In 2020, 19.3 million new cancer cases were reported, with that number expected to rise to 30.2 million by 2040. This increase in cancer incidence can be attributed to the growing geriatric population as well as the overall population.

  • The increase in adoption of latest technologies and growth in collaborations

Rising technological advancements is the vital factor escalating the market growth, also increasing initiatives undertaken by governments and global health organizations to spread awareness about cancer, rising growth in the number of private diagnostic centers, rising public-private partnerships to enhance the infrastructure of diagnostic imaging centers, rising Fda support for biomarker development and rising launch of new flow cytometry reagents for diagnostics and drug discovery are the major factors among others driving the cancer diagnostics market..

  • Government investments for healthcare interoperability

The increase in the funding by the federal government to drive the adoption of these solutions further influence the market. Additionally, the surge in healthcare expenditure, advancements in healthcare infrastructure, and high demand for expanded care delivery positively affect the cancer diagnostics market.

Opportunities

Increasing personalised medicine, mass cytometry development, and the combination of cell- and bead-based flow cytometry technologies, improving healthcare infrastructure in emerging markets, and the rise of miniaturised and technologically advanced devices will all create new opportunities for the cancer diagnostics market.

Restraints/Challenges

Rising capital investments and low benefit-cost ratio for biomarkers, rising helium shortage and rising risk of high radiation exposure likely to limit the use of CT scanners are among the major factors obstructing market growth, while rising stringent regulatory guidelines and rising adoption of refurbished diagnostic imaging systems will further challenge the growth of the cancer diagnostics market during the forecast period.

This cancer diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cancer diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Cancer diagnostics Market

National lockdowns, government regulations, and an increase in infection rates across countries all had a significant financial impact on neurology hospitals and clinics. Several hospitals and clinics have seen a decrease in patient visits as a result of COVID-19, ultimately reducing client contact. Furthermore, many cancer diagnostics have been pushed back as a result of the COVID-19 crisis. There is a global shortage of medical care for conditions other than COVID-19, which has had a negative impact on the cancer diagnostics market. At the same time, the limited availability of healthcare personnel around the world is another factor that has a negative impact on the cancer diagnostics market.

Recent Development

  • Siemens Healthineers will launch Magnetom Free in November 2021. Star is a low-cost whole-body MRI scanner that is intended to improve global access to magnetic resonance imaging.
  • Agilent Technologies Inc. announced in October 2021 that its PD-L1 IHC 22C3 pharmDx assay has been labelled for use in Triple-Negative Breast Cancer (TNBC) in the European Union.

Global Cancer diagnostics Market Scope

The cancer diagnostics market is segmented on the basis of type, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Image testing
  • Biomarkers testing
  • In vitro diagnostic testing
  • others

On the basis of type, cancer diagnostics market is segmented into imaging testing, biomarkers testing, in vitro diagnostic testing, biopsy and others.

Application

  • lung cancer
  • breast cancer
  • colorectal cancer
  • melanoma cancer
  • prostate cancer
  • liver cancer
  • others

Based on application, the cancer diagnostics market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma cancer, prostate cancer, liver cancer and others.

End User

  • diagnostic centers
  • Research Institutes
  • Hospitals
  • Others
  • clinics

The cancer diagnostics market is also segmented on the basis of end-user into diagnostic centers, hospitals and clinics, research institutes and others..

Cancer diagnostics Market Regional Analysis/Insights

The cancer diagnostics market is analysed and market size insights and trends are provided by country, type, application and end users as referenced above.

The countries covered in the cancer diagnostics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the cancer diagnostics market due to the increasing presence of numerous biotechnology and medical device companies, increased funding available for research and development projects, and the region's high adoption of advanced technologies. Due to rising favourable government policies supporting the growth of the manufacturing industry, as well as lower manufacturing costs in this region, Asia-Pacific is expected to be the fastest growing region in terms of cancer diagnostics market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The cancer diagnostics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for cancer diagnostics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cancer diagnostics market. The data is available for historic period 2010-2020.

Competitive Landscape and Cancer diagnostics Market Share Analysis

The cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cancer diagnostics market.

Some of the major players operating in the cancer diagnostics market are

  • Abbott. (US)
  • DiagnoCure Inc. (Canada)
  • Thermo Fisher Scientific Inc. (US)
  • Illumina, Inc. (US)
  • QIAGEN (Germany)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Agilent Technologies, Inc. (US)
  • Quest Diagnostics Incorporated. (US)
  • Merck KGaA, (Germany)
  • Hologic, Inc. (US)
  • BD. (US)
  • GlaxoSmithKline plc. (UK)
  • Novartis AG (Switzerland)
  • Bristol-Myers Squibb Company (US)
  • Eli Lilly and Company (US)
  • Pfizer, Inc. (US)
  • Genomic Health, Inc. (US)
  • bioMérieux SA (France)
  • Astellas Pharma Inc. (Japan)
  • Myriad Genetics, Inc. (US)

Research Methodology: Global Cancer diagnostics Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLE : GLOBAL CANCER DIAGNOSTICS MARKET

TABLE 1 GLOBAL CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 2 GLOBAL PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY REGION, 2015– 2024 (USD MILLION) TABLE 3 GLOBAL POLYMERASE CHAIN REACTION MARKET, BY REGION, 2015– 2024 (USD MILLION) TABLE 4 GLOBAL IN SITU HYBRIDIZATION MARKET, BY REGION, 2015– 2024 (USD MILLION) TABLE 5 GLOBAL IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2015– 2024 (USD MILLION) TABLE 6 GLOBAL NEXT GENERATION SEQUENCING MARKET, BY REGION, 2015– 2024 (USD MILLION) TABLE 7 GLOBAL DNA MICROARRAYS MARKET, BY REGION, 2015– 2024 (USD MILLION) TABLE 8 GLOBAL FLOW CYTOMETRY MARKET, BY REGION, 2015– 2024 (USD MILLION) TABLE 9 GLOBAL INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY REGION, 2015– 2024 (USD MILLION) TABLE 10 GLOBAL INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING BY REGION, 2015– 2024 (USD MILLION) TABLE 11 GLOBAL INSTRUMENT BASED CNACER DIAGNOSTICS MARKET, BY BIOPSY , BY REGION, 2015– 2024 (USD MILLION) TABLE 12 GLOBAL CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION) TABLE 13 WORLDWIDE LUNG CANCER INCIDENCES TABLE 14 GLOBAL CANCER DIAGNOSTICS MARKET, LUNG CANCER, BYREGION, 2015 – 2024 (USD MILLION) TABLE 15 WORLDWIDE BREAST CANCER INCIDENCES TABLE 16 GLOBAL CANCER DIAGNOSTICS MARKET, BY BREAST CANCER, BY REGION, 2015 – 2024 (USD MILLION) TABLE 17 WORLDWIDE COLORECTAL CANCER INCIDENCES TABLE 18 GLOBAL CANCER DIAGNOSTICS MARKET, BY COLORECTAL CANCER, BY REGION, 2015 – 2024 (USD MILLION) TABLE 19 WORLDWIDE MELANOMA CANCER INCIDENCES TABLE 20 GLOBAL CANCER DIAGNOSTICS MARKET, BY MELANOMA , BY REGION2015 – 2024 (USD MILLION) TABLE 21 ESTIMATED NEW CASES OF CANCER IN 2017 TABLE 22 GLOBAL CANCER DIAGNOSTICS MARKET, BY OTHERS, BY REGION, 2015 – 2024 (USD MILLION) TABLE 23 GLOBAL CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY, 2015 – 2024 (USD MILLION) TABLE 24 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION) TABLE 25 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 26 NORTH AMERICA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 27 NORTH AMERICA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 28 NORTH AMERICA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 29 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 30 U.S.CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 31 U.S. PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 32 U.S. INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 33 U.S. INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 34 U.S. CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 35 CANADA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 36 CANADA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 37 CANADA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 38 CANADA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 39 CANADA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 40 MEXICO CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 41 MEXICO PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 42 MEXICO INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 43 MEXICO INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 44 MEXICO CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 45 EUROPE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2015 – 2024(USD MILLION) TABLE 46 EUROPE CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 47 EUROPE PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 48 EUROPE INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 49 EUROPE INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 50 EUROPE CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 51 GERMANY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 52 GERMANY PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 53 GERMANY INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 54 GERMANY INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 55 GERMANY CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 56 FRANCE CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 57 FRANCE PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 58 FRANCE INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 59 FRANCE INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 60 FRANCE CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 61 U.K.CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 62 U.K. PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 63 U.K. INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 64 U.K. INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 65 U.K. CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 66 ITALY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 67 ITALY PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 68 ITALY INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 69 ITALY INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 70 ITALY CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 71 SPAIN CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 72 SPAIN PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 73 SPAIN INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 74 SPAIN INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 75 SPAIN CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 76 RUSSIA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 77 RUSSIA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 78 RUSSIA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 79 RUSSIA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 80 RUSSIA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 81 TURKEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 82 TURKEY PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 83 TURKEY INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 84 TURKEY INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 85 TURKEY CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 86 BELGIUM CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 87 BELGIUM PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 88 BELGIUM INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 89 BELGIUM INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 90 BELGIUM CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 91 NETHERLANDSCANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 92 NETHERLANDS PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 93 NETHERLANDS INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 94 NETHERLANDS INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 95 NETHERLANDS CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 96 SWITZERLAND CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 97 SWITZERLAND PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 98 SWITZERLAND INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 99 SWITZERLAND INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 100 SWITZERLAND CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 101 REST OF EUROPECANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 102 REST OF EUROPE PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 103 REST OF EUROPE INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 104 REST OF EUROPE INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 105 REST OF EUROPE CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 106 APAC CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION) TABLE 107 APAC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 108 APAC PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 109 APAC INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 110 APAC INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 111 APAC CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 112 JAPANCANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 113 JAPAN PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 114 JAPAN INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 115 JAPAN INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 116 JAPAN CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 117 CHINA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 118 CHINA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 119 CHINA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 120 CHINA INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 121 CHINA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 122 INDIACANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 123 INDIA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 124 INDIA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 125 INDIA INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 126 INDIA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 127 SOUTH KOREA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 128 SOUTH KOREA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 129 SOUTH KOREA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 130 SOUTH KOREA INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 131 SOUTH KOREA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 132 AUSTRALIACANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 133 AUSTRALIA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 134 AUSTRALIA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 135 AUSTRALIA INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 136 AUSTRALIA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 137 THAILAND CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 138 THAILAND PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 139 THAILAND INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 140 THAILAND INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 141 THAILAND CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 142 SINGAPORE CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 143 SINGAPORE PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 144 SINGAPORE INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 145 SINGAPORE INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 146 SINGAPORE CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 147 MALAYSIA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 148 MALAYSIA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 149 MALAYSIA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 150 MALAYSIA INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 151 MALAYSIA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 152 INDONESIA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 153 INDONESIA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 154 INDONESIA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 155 INDONESIA INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 156 INDONESIA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 157 PHILIPPINES CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 158 PHILLIPINES PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 159 PHILIPPINES INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 160 PHILIPPINES INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 161 PHILIPPINES CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 162 REST OF APAC CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 163 REST OF APAC PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 164 REST OF APAC INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 165 REST OF APAC INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 166 REST OF APAC CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 167 SOUTH AMERICA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION) TABLE 168 SOUTH AMERICA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 169 SOUTH AMERICA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 170 SOUTH AMERICA INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 171 SOUTH AMERICA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 172 SOUTH AMERICA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 173 BRAZIL CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 174 BRAZIL PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 175 BRAZIL INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 176 BRAZIL INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 177 BRAZIL CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 178 REST OF SOUTH AMERICACANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 179 REST OF SOUTH AMERICA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 180 REST OF SOUTH AMERICA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 181 REST OF SOUTH AMERICA INSTRUMENT BASED IMAGING CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 182 REST OF SOUTH AMERICA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 183 MEA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION) TABLE 184 MEA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 185 MEA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 186 MEA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 187 MEA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 188 MEA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 189 SOUTH AFRICA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION) TABLE 190 SOUTH AFRICA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 191 SOUTH AFRICA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION) TABLE 192 SOUTH AFRICA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION) TABLE 193 SOUTH AFRICA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION) TABLE 194 REST OF MEACANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The market value for cancer diagnostics market is expected USD 28.21 billion by 2029.
The Cancer Diagnostics Market is to grow at a CAGR of 7.29% during the forecast by 2029.
On the basis of application, the Cancer Diagnostics Market is segmented into Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma Cancer, Prostate Cancer, Liver Cancer, Others.
The major players operating in the Cancer Diagnostics Market are Abbott. (US), DiagnoCure Inc. (Canada), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), QIAGEN (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), Quest Diagnostics Incorporated. (US), Merck KGaA, (Germany), Hologic, Inc. (US), BD. (US), GlaxoSmithKline plc. (UK), Novartis AG (Switzerland), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Pfizer, Inc. (US), Genomic Health, Inc. (US), bioMérieux SA (France), Astellas Pharma Inc. (Japan) and Myriad Genetics, Inc. (US).

Browse Related Reports

North America Cancer Diagnostics Market – Industry Trends and Forecast to 2028

Europe Cancer Diagnostics Market – Industry Trends and Forecast to 2029

Asia-Pacific Cancer Diagnostics Market – Industry Trends and Forecast to 2029

Global Noninvasive Cancer Diagnostics Market – Industry Trends and Forecast to 2029

Global Prostate Cancer Diagnostics Market – Industry Trends and Forecast to 2028

Global Breast Cancer Diagnostics Market – Industry Trends and Forecast to 2027

Global Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2029

Global Ovarian Cancer Diagnostics Market – Industry Trends and Forecast to 2027

Global Liver Cancer Diagnostics Market – Industry Trends and Forecast to 2027

Global Next Generation Cancer Diagnostics Market – Industry Trends and Forecast to 2029

Global Adrenal Cancer Diagnostics Market – Industry Trends and Forecast to 2027

Global Thyroid Cancer Diagnostics Market – Industry Trends and Forecast to 2027

Asia-Pacific Prostate Cancer Diagnostics Market – Industry Trends and Forecast to 2028

Europe Prostate Cancer Diagnostics Market – Industry Trends and Forecast to 2028

Middle East and Africa Prostate Cancer Diagnostics Market – Industry Trends and Forecast to 2028

North America Prostate Cancer Diagnostics Market – Industry Trends and Forecast to 2028

Global Non-Small Cell Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2028

North America Non-Small Cell Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2028

Europe Non-Small Cell Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2028

Asia-Pacific Non-Small Cell Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2028

Middle East And Africa Non-Small Cell Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2028

Global Gastric Cancer Diagnostics Market – Industry Trends and Forecast to 2028

Asia-Pacific Gastric Cancer Diagnostics Market – Industry Trends and Forecast to 2028

Middle East and Africa Gastric Cancer Diagnostics Market – Industry Trends and Forecast to 2028

North America Gastric Cancer Diagnostics Market – Industry Trends and Forecast to 2028

Europe Gastric Cancer Diagnostics Market – Industry Trends and Forecast to 2028